Author

Matthew Fuchter

Imperial College LondonORCID 0000-0002-1767-7072Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 2 Assay:bulk RNA-seq· 1 Research Focus:differential expression· 1 Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Approach:statistical model· 1

Frequent Co-Authors

Alice Ormrod· 1 shared Anabel Varela‐Carver· 1 shared Ash K. BahliD· 1 shared Catherine FickeniD· 1 shared Charlotte Lynne BevaniD· 1 shared Chun‐Fui LaiiD· 1 shared Claire Kennedy DietrichiD· 1 shared Colin NixoniD· 1 shared

Activity by Year

2023-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 21 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperMolecular Biology

Alice Ormrod

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Phenotype-dependent subtyping exposes high MYC activity as a targetable dependency in LuAd

Sarah Laing, Isabel Dye, Ryan M. Byrne, Eva C. Freckmann, Robin Shaw, Shahanawaz Ali, Sophie Heese, Yoana Doncheva, Catherine Ficken, Jennifer Doig, Sudhir B. Malla, Saira Ghafoor, Sophie McLaughlin, Colin Nixon, Graeme Clark, , Daniel J. Murphy

The paper identifies high MYC activity as a targetable feature in lung adenocarcinoma using phenotype-based subtyping and shows sensitivity to a dual inhibitor of MYC co-factors.

bioRxiv · May 1, 2026 · PreprintCancer Biology

The CDK7 inhibitor CT7001 (Samuraciclib) targets proliferation pathways to inhibit advanced prostate cancer

Theodora A. Constantin, Anabel Varela‐Carver, Kyle K. Greenland, Gilberto Serrano de Almeida, Ellen Olden, Lucy Penfold, Simon Ang, Alice Ormrod, Damien A. Leach, Chun‐Fui Lai, Edward Ainscow, Ash K. Bahl, David Carling, Matthew John Fuchter, Simak Ali, Charlotte Lynne Bevan

This study investigates the antitumour activity of CT7001, a CDK7 inhibitor, in castration-resistant prostate cancer models, showing it inhibits proliferation and enhances enzalutamide efficacy.

British Journal of Cancer · Apr 19, 2023Peer-reviewedMolecular Biology